Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1438-1443

  Makino, Toshiaki ^a,b,c   Ohtake, Nobuhiro ^a,b,c   Watanabe, Akito ^a,b,c   Tsuchiya, Naoko ^a,b,c   Imamura, Sachiko ^a,b,c   Lizuka, Seiichi ^a,b,c   Inoue, Makoto ^a,b,c   Mizukami, Hajime ^a,b,c  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b TSUMURA AND CO   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 3 MONOGLUCURONYL GLYCYRRHETINIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINO ACID; BILE ACID; DRUG METABOLITE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HYALURONIC ACID; MULTIDRUG RESISTANCE PROTEIN 2; PHOSPHOLIPID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE ACID BLOOD LEVEL; BILIARY EXCRETION; BODY WEIGHT; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; HYPERALDOSTERONISM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; LIVER WEIGHT; MALE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GLYCYRRHIZIC ACID; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LIVER; MALE; RATS; RATS, WISTAR;

RATTUS;

EID: 46449125861     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021089     Document Type: Article

References (31)

1. Akao T (1998) Distribution of enzymes involved in the metabolism of glycyrrhizin in various organs of rat. Biol Pharm Bull 21:1036-1044.
2. Akao T, Hattori M, Kanaoka M, Yamamoto K, Namba T, and Kobashi T (1991) Hydrolysis of glycyrrhizin to 18β-glycyrrhetyl monoglucuronide by lysosomal β-D-glucuronidase of animal livers. Biochem Pharmacol 41:1025-1029.
3. Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, and Sugiyama Y (2001) Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta 1511:7-16.
4. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, and Kumada H (1997) The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500.
5. Bernardi M, D'Intino PE, Trevisani F, Cantelli-Forti G, Raggi MA, Turchetto E, and Gasbarrini
6. G (1994) Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. Life Sci 55:863-872.
7. Bühler H, Perschel FH, Fitzner R, and Hierholzer K (1994) Endogenous inhibitors of 11β-OHSD: existence and possible significance. Steroids 59:131-135.
8. Conn JW, Rovner DR, and Cohen EL (1968) Licorice-induced pseudoaldosteronism: hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA 205:492-496.
9. Endoh T, Tang Q, Denda A, Noguchi O, Kobayashi E, Tamura K, Horiguchi K, Ogasawara H, Tsujiuchi T, Nakae D, et al. (1996) Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis 17:467-475.
10. Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, and Sugiyama Y (2000) Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 292:433-439.
11. Homma M, Ishihara M, Qian W, and Kohda Y (2006) Effects of long term administration of Shakuyaku-Kanzo-To and Shosaiko-To on serum potassium levels. Yakugaku Zasshi 126:973-978.
12. Hosokawa S, Tagaya O, Mikami T, Nozaki Y, Kawaguchi A, Yamatsu K, and Shamoto M (1992) A new rat mutant with chronic conjugated hyperbilirubinemia and renal glomerular lesions. Lab Anim Sci 42:27-34.
13. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, and Sugiyama Y (1997) Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 272:G16-G22.
14. Jin H, Yamamoto N, Uchida K, Terai S, and Sakaida I (2007) Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 364:801-807.
15. Kanaoka M, Yano S, Kato H, and Nakada T (1986) Synthesis and separation of 18β-glycyrrhetyl monoglucuronide from serum of a patient with glycyrrhizin-induced pseudo-aldosteronism. Chem Pharm Bull 34:4978-4983.
16. Kato H, Kanaoka M, Yano S, and Kobayashi M (1995) 3-Monoglucuronyl- glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab 80:1929-1933.
17. Keppler D and Konig J (1997) Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 11:509-516.
18. Kumada H (2002) Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 62 (Suppl 1):94-100.
19. Morimoto Y and Nakajima C (1991) Pseudoaldosteronism induced by licorice derivatives in Japan. J Trad Med 8:1-22.
20. Nakae D, Yoshiji H, Mizumoto Y, Horiguchi K, Shiraiwa K, Tamura K, Denda A, and Konishi Y(1992) High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 52:5042-5045.
21. Ohtake N, Kido A, Kubota K, Tsuchiya N, Morita T, Kase Y, and Takeda S (2007) A possible involvement of 3-monoglucuronyl-glycyrrhetinic acid, a metabolite of glycyrrhizin (GL), in GL-induced pseudoaldosteronism. Life Sci 80:1545-1552.
22. Okada K, Shoda J, Kano M, Suzuki S, Ohtake N, Yamamoto M, Takahashi H, Utsunomiya H, Oda K, Sato K, et al. (2007) Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. Am J Physiol Gastrointest Liver Physiol 292:G1450-G1463.
23. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, and DeJongh J (2001) The pharma-cokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev 33:125-147.
24. Sakaida I, Matsumura Y, Kubota M, Kayano K, Takenaka K, and Okita K (1996) The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Hepatology 23:755-763.
25. Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, et al. (2004) Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 39:167-178.
26. Sigurjónsdóttir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, and Wallerstedt S (2001) Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens 15:549-552.
27. Tanahashi T, Mune T, Morita H, Tanahashi H, Isomura Y, Suwa T, Daido H, Gomez-Sanchez CE, and Yasuda K (2002) Glycyrrhizic acid suppresses type 2 11β-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol 80:441-447.
28. Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F, and Ozercan IH (2007) Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 52:2006-2014.
29. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, and Schalm SW (1998) Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12:199-205.
30. van Rossum TG, Vulto AG, Hop WC, and Schalm SW (2001) Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 96:2432-2437.
31. Yamamura Y, Tanaka N, Santa T, Kotaki H, Aikawa T, Uchino K, Osuga T, Sawada Y, and Iga T(1995) The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. Biopharm Drug Dispos 16:13-21.